Preview

Neurology, Neuropsychiatry, Psychosomatics

Advanced search

Efficacy and safety of intravenous thrombolytic therapy in patients with ischemic stroke and mild neurological deficit

https://doi.org/10.14412/2074-2711-2025-3-41-48

Abstract

Intravenous thrombolytic therapy (IV TLT) is the main method of reperfusion therapy for ischemic stroke (IS). Almost half of IS patients present with a mild neurological deficit at onset, for which the efficacy of IV TLT remains controversial.

Objective: to assess the efficacy and safety of IV TLT in patients with IS and mild neurological deficit depending on the degree of stenosis of the main arteries of the head (MAH), regardless of the level of disability.

Material and methods. A total of 166 patients with IS and mild neurological deficit (less than 5 points on the NIHSS stroke severity scale) were observed: 82 patients received IV TLT, and 84 patients formed the comparison group.

Results. At hospital discharge, IS patients who received IV TLT showed a lower severity of neurological deficit on the NIHSS scale (U(82,84)=1882; p<0.001) and a better functional outcome according to the modified Rankin Scale (U(82,84)=1854; p<0.001) and the Rivermead Mobility Index (U(82,84)=1795; p<0.001). In the subgroup of patients with significant MAH stenosis, statistically significant advantages of IV TLT were also found according the NIHSS, Rankin Scale, and Rivermead Index. Hemorrhagic transformations occurred in the IV TLT group in 14 patients, and in the comparison group in 6 patients (only a trend toward increased frequency).

Conclusion. IV TLT in patients with IS and mild neurological deficit improves functional outcomes in the acute period of stroke. IV TLT is also effective in the subgroup of patients with significant MAH stenosis.

About the Authors

M. R. Suleymanova
Kazan State Medical University, Ministry of Health of Russia
Russian Federation

Madina Rinatovna Suleymanova

49, Butlerova St., Kazan 420012


Competing Interests:

There are no conflicts of interest



T. V. Danilova
Kazan State Medical University, Ministry of Health of Russia; Interregional Clinical and Diagnostic Center
Russian Federation

49, Butlerova St., Kazan 420012

12a, Karbysheva St., Kazan 420101


Competing Interests:

There are no conflicts of interest



D. R. Khasanova
Kazan State Medical University, Ministry of Health of Russia; Interregional Clinical and Diagnostic Center
Russian Federation

49, Butlerova St., Kazan 420012

12a, Karbysheva St., Kazan 420101


Competing Interests:

There are no conflicts of interest



References

1. Alasheev AM, Belkin AA, BogatyrevaMD, editors. Protocol of thrombolytic therapy for acute ischemic stroke. St. Petersburg; 2023. 52 p. (In Russ.)].

2. Merlino G, Nesi L, Vergobbi P, et al. The use of alteplase, although safe, does not offer clear clinical advantages when mild stroke is non-disabling. Front Neurol. 2023 Jul 17;14:1212712. doi: 10.3389/fneur.2023.1212712

3. Sykora M, Krebs S, Simader F, et al; Austrian Stroke Unit Registry Collaborators. Intravenous thrombolysis in stroke with admission NIHSS score 0 or 1. Int J Stroke. 2022 Jan;17(1):109-19. doi: 10.1177/1747493021991969. Epub 2021 Feb 10.

4. Khatri P, Conaway MR, Johnston KC; Acute Stroke Accurate Prediction Study (ASAP) Investigators. Ninety-day outcome rates of a prospective cohort of consecutive patients with mild ischemic stroke. Stroke. 2012 Feb;43(2):560-2. doi: 10.1161/STROKEAHA.110.593897. Epub 2011 Nov 3.

5. Ali SF, Siddiqui K, Ay H, et al. Baseline Predictors of Poor Outcome in Patients Too Good to Treat With Intravenous Thrombolysis. Stroke. 2016 Dec;47(12):2986-92. doi: 10.1161/STROKEAHA.116.014871. Epub 2016 Nov 10.

6. Chen HS, Cui Y, Zhou ZH, et al; ARAMIS Investigators. Dual Antiplatelet Therapy vs Alteplase for Patients With Minor Nondisabling Acute Ischemic Stroke: The ARAMIS Randomized Clinical Trial. JAMA. 2023 Jun 27;329(24):2135-44. doi: 10.1001/jama.2023.7827

7. Berge E, Whiteley W, Audebert H, et al. European Stroke Organisation (ESO) guidelines on intravenous thrombolysis for acute ischaemic stroke. Eur Stroke J. 2021 Mar;6(1):I-LXII. doi: 10.1177/2396987321989865. Epub 2021 Feb 19.

8. All-Russian Society of Neurologists, National Association for Stroke Control, Association of Neurosurgeons of Russia, IPO “Association of Neuroanesthesiologists and Neurointensivists”, Union of Rehabilitologists of Russia. Clinical recommendations. Ischemic stroke and transient ischemic attack in adults. 2024. Available at: https://cr.minzdrav.gov.ru/preview-cr/814_1 (accessed 30.01.2025 (In Russ.)].

9. Powers WJ, Rabinstein AA, Ackerson T, et al; American Heart Association Stroke Council. 2018 Guidelines for the Early Management of Patients With Acute Ischemic Stroke: A Guideline for Healthcare Professionals From the American Heart Association/American Stroke Association. Stroke. 2018 Mar;49(3):e46-e110. doi: 10.1161/STR.0000000000000158. Epub 2018 Jan 24. Erratum in: Stroke. 2018 Mar;49(3):e138. doi: 10.1161/STR.0000000000000163. Erratum in: Stroke. 2018 Jun;49(6):e233-e234. doi: 10.1161/STR.0000000000000172

10. Seners P, Perrin C, Lapergue B, et al; MINOR-STROKE Collaborators. Bridging Therapy or IV Thrombolysis in Minor Stroke with Large Vessel Occlusion. Ann Neurol. 2020 Jul;88(1):160-9. doi: 10.1002/ana.25756. Epub 2020 May 14.

11. Adams HP Jr, Bendixen BH, Kappelle LJ,et al. Classification of subtype of acute ischemic stroke. Definitions for use in a multicenter clinical trial. TOAST. Trial of Org 10172 in Acute Stroke Treatment. Stroke. 1993 Jan;24(1):35-41. doi: 10.1161/01.str.24.1.35

12. Khatri P, Kleindorfer DO, Devlin T, et al;PRISMS Investigators. Effect of Alteplase vs Aspirin on Functional Outcome for Patients With Acute Ischemic Stroke and Minor Nondisabling Neurologic Deficits: The PRISMS Randomized Clinical Trial. JAMA. 2018 Jul 10;320(2):156-66. doi: 10.1001/jama.2018.8496

13. Braksick SA, Rabinstein AA. ThrombolysisIs Not Indicated for Minor Strokes If They Are Truly Nondisabling. Stroke. 2024 Apr;55(4):893-4. doi: 10.1161/STROKEA-HA.124.046549

14. Marsh EB, Girgenti S, Llinas EJ, Brunson AO. Outcomes in Patients with Minor Stroke: Diagnosis and Management in the Post-thrombectomy Era. Neurotherapeutics. 2023 Apr;20(3):732-43. doi: 10.1007/s13311-023-01349-5. Epub 2023 Feb 8.

15. Yaghi S, Willey JZ, Khatri P. Minorischemic stroke: Triaging, disposition, and outcome. Neurol Clin Pract. 2016 Apr;6(2):157-63. doi: 10.1212/CPJ.0000000000000234

16. Alhazzani A, Al-Ajlan FS, Alkhiri A, et al.Intravenous alteplase in minor nondisabling ischemic stroke: A systematic review and metaanalysis. Eur Stroke J. 2024 Sep;9(3):521-9. doi: 10.1177/23969873241237312. Epub 2024 Mar 11.

17. Cui Y, He C, Li ZA, et al. Dual Antiplatelet Versus Alteplase for Early Neurologic Deterioration in Minor Stroke With Versus Without Large Vessel Occlusion: Prespecified Post Hoc Analysis of the ARAMIS Trial. Stroke. 2024 Nov;55(11):2590-8. doi: 10.1161/STROKEAHA.124.048248. Epub 2024 Oct 10. 18. Tsivgoulis G, Goyal N, Katsanos AH, et al. Intravenous thrombolysis for large vessel or distal occlusions presenting with mild stroke severity. Eur J Neurol. 2020 Jun;27(6):1039-47. doi: 10.1111/ene.14199. Epub 2020 Mar 23.


Review

For citations:


Suleymanova MR, Danilova TV, Khasanova DR. Efficacy and safety of intravenous thrombolytic therapy in patients with ischemic stroke and mild neurological deficit. Nevrologiya, neiropsikhiatriya, psikhosomatika = Neurology, Neuropsychiatry, Psychosomatics. 2025;17(3):41-48. (In Russ.) https://doi.org/10.14412/2074-2711-2025-3-41-48

Views: 20


Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 License.


ISSN 2074-2711 (Print)
ISSN 2310-1342 (Online)